Forte Research Systems, Inc.
, a developer of clinical trial management systems (
CTMS
), and
Virtify, Inc.
, a provider of structured content management software solutions for life sciences, announced today a partnership that aims to simplify compliance with disclosure requirements of the Food and Drug Administration Amendments Act (FDAAA). The agreement addresses the increasingly stringent regulations imposed on clinical research institutions.
The integration will take place between Forte's OnCore® system, an enterprise-class
clinical research management system
utilized by academic medical centers and cancer centers, and the
Virtify CTRR
(Clinical Trial Registration & Results) software, which streamlines and automates the mandatory disclosure postings to the ClinicalTrials.gov online registry and results database.
"Collaborating with Virtify allows us to provide a seamless and sophisticated experience for OnCore users as they comply with these regulations," said Srini Kalluri, Founder, CEO, and Chief Customer Officer at Forte. "OnCore is a proven system that supports streamlined management of robust portfolios of clinical trials. Coupled with the many benefits of the Virtify CTRR, OnCore becomes the most comprehensive solution available for compliance with clinical trial disclosure requirements."
Among the benefits offered by Virtify CTRR is an easy-to-use centralized compliance monitoring system for clinical trials. It offers the status of all trial disclosures and helps users proactively identify their risks related to trial disclosure and non-compliances.
When integrated with the OnCore system, the Virtify solution will provide an end-to-end disclosure solution. "It will extend CTRR's robust disclosure process management features to the OnCore system, which in turn will be able to share data directly with Virtify CTRR," said Satish Tadikonda, CEO of Virtify. "The ability of the systems to communicate means that duplicate data entry will be eliminated."
The new agreement is the most recent among several collaborations in which Forte has joined with industry leaders to provide comprehensive solutions and eliminate data silos. "With Virtify's extensive experience and expertise in the clinical trial disclosure arena, it makes perfect sense to partner with them rather than reinventing the wheel," Kalluri said. "This will continue to be our strategy in order to bring greater efficiencies to the industry."
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
WCG Randomized 1,600 Participants for RSV Vaccine Trial
October 31st 2024A top 5 sponsor turned to WCG to recruit expecting mothers for its Phase III RSV vaccine trial. WCG support covered multiple countries and contributed almost one third of overall randomizations in the supported countries, bringing the study in ahead of schedule despite delays due to COVID-19 impacts on RSV seasonality. The sponsor met study timeline past enrollment by continuing to work with WCG’s retention support.